Advertisement

Tumor Biology

, Volume 35, Issue 5, pp 4937–4941 | Cite as

Genetic association of CHEK2, GSTP1, and ERCC1 with glioblastoma in the Han Chinese population

  • Yu-Shu Dong
  • Wu-Gang Hou
  • Xiao-Lan Li
  • Tian-Bo Jin
  • Yue Li
  • Da-Yun Feng
  • De-Bao Liu
  • Guo-Dong Gao
  • Zhong-Min Yin
  • Huai-Zhou Qin
Research Article

Abstract

Glioblastoma (GBM), a deadly brain tumor, is the most malignant glioma. It mainly occurs in adults and occurs significantly more in males than in females. We genotyped 19 tag single nucleotide polymorphisms (tSNPs) from 13 genes in a case–control study of the Han Chinese population to identify genetic factors contributing to the risk of GBM. These tSNPs were genotyped by Sequenom MassARRAY RS1000. Statistical analysis was performed using χ 2 test and SNPStats, a website software. Using χ 2 test, we found that the distribution of two tSNPs (rs2267130 in checkpoint kinase 2 (CHEK2), p = 0.040; rs1695 in GSTP1, p = 0.023) allelic frequencies had significant difference between cases and controls. When we analyzed all of the tSNPs using the SNPStats software, we found that rs1695 in GSTP1 decreased the risk of GBM in log-additive model (OR = 0.56, 95 % CI, 0.34–0.94, p = 0.022). Besides, we found that there is an interaction between rs3212986 in excision repair cross-complementing group 1 (ERCC1) and gender under codominant and recessive models. The gene polymorphisms in CHEK2, GSTP1, and ERCC1 may be involved in GBM in the Han Chinese population. Since our sample size is small, further investigation needs to be performed.

Keywords

Glioblastoma (GBM) Tag single nucleotide polymorphism (tSNP) Case–control study CHEK2 GSTP1 ERCC1 

Notes

Acknowledgments

This work was supported by China Postdoctoral Science Foundation funded projects (no. 2012M521798). We would also like to thank BioScience Writers for their assistance in the preparation of this manuscript.

Conflicts of interest

None

References

  1. 1.
    Liu Y, Shete S, Etzel CJ, Scheurer M, Alexiou G, Armstrong G, et al. Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. J Clin Oncol. 2010;28:2267–74.CrossRefGoogle Scholar
  2. 2.
    Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010;60:166–93.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Haque A, Banik NL, Ray SK. Molecular alterations in glioblastoma: potential targets for immunotherapy. Prog Mol Biol Transl Sci. 2011;98:187–234.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Schwartzbaum JA, Xiao Y, Liu Y, Tsavachidis S, Berger MS, Bondy ML, et al. Inherited variation in immune genes and pathways and glioblastoma risk. Carcinogenesis. 2010;31:1770–7.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bethke L, Webb E, Murray A, Schoemaker M, Johansen C, Christensen HC, et al. Comprehensive analysis of the role of DNA repair gene polymorphisms on risk of glioma. Hum Mol Genet. 2008;17:800–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Rajaraman P, Wang SS, Rothman N, Brown MM, Black PM, Fine HA, et al. Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev. 2007;16:1655–61.CrossRefPubMedGoogle Scholar
  7. 7.
    Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009;41:899–904.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Andersson U, Schwartzbaum J, Wiklund F, Sjostrom S, Liu Y, Tsavachidis S, et al. A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. Acta Oncol. 2010;49:767–75.CrossRefPubMedGoogle Scholar
  9. 9.
    Rajaraman P, Brenner AV, Butler MA, Wang SS, Pfeiffer RM, Ruder AM, et al. Common variation in genes related to innate immunity and risk of adult glioma. Cancer Epidemiol Biomarkers Prev. 2009;18:1651–8.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Liu Y, Shete S, Hosking F, Robertson L, Houlston R, Bondy M. Genetic advances in glioma: susceptibility genes and networks. Curr Opin Genet Dev. 2010;20:239–44.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39:347–51.CrossRefPubMedGoogle Scholar
  12. 12.
    Adamec C. Example of the use of the nonparametric test. Test χ 2 for comparison of 2 independent examples. Cesk Zdrav. 1964;12:613–9.PubMedGoogle Scholar
  13. 13.
    Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22:1928–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Bland JM, Altman DG. Statistics notes. The odds ratio. BMJ. 2000;320:1468.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Cox DG, Hankinson SE, Hunter DJ. The erbB2/ HER2/neu receptor polymorphism Ile655Val and breast cancer risk. Pharmacogenet Genomics. 2005;15:447–50.CrossRefPubMedGoogle Scholar
  16. 16.
    Xiang S, Sun Z, He Q, Yan F, Wang Y, Zhang J. Aspirin inhibits ErbB2 to induce apoptosis in cervical cancer cells. Med Oncol. 2010;27:379–87.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhou RM, Niu CX, Wang N, Chen ZF, Lei SE, Li Y. ERCC1 gene +262A/C polymorphism associated with risk of gastric cardiac adenocarcinoma in nonsmokers. Arch Med Res. 2012;43:67–74.CrossRefPubMedGoogle Scholar
  18. 18.
    Zhang LQ, Wang J, Xu L, Zhou JN, Guan X, Jiang F, et al. Nucleotide excision repair gene ERCC1 polymorphisms contribute to cancer susceptibility: a meta-analysis. Mutagenesis. 2012;27:67–76.CrossRefPubMedGoogle Scholar
  19. 19.
    Ogino S, Hazra A, Tranah GJ, Kirkner GJ, Kawasaki T, Nosho K, et al. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis. 2007;28:1985–90.CrossRefPubMedGoogle Scholar
  20. 20.
    Doecke J, Zhao ZZ, Pandeya N, Sadeghi S, Stark M, Green AC, et al. Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma. Int J Cancer. 2008;123:174–80.CrossRefPubMedGoogle Scholar
  21. 21.
    Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol. 2008;26:542–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Kleibl Z, Havranek O, Hlavata L, Novotny J, Sevcik J, Pohlreich P, et al. The CHEK2 gene L157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population. Eur J Cancer. 2009;45:618–24.CrossRefPubMedGoogle Scholar
  23. 23.
    Xu Z, Zhu H, Luk JM, Wu D, Gu D, Gong W, et al. Clinical significance of SOD2 and GSTP1 gene polymorphisms in Chinese patients with gastric cancer. Cancer. 2012;118:5489–96.CrossRefPubMedGoogle Scholar
  24. 24.
    Li G, Jin TB, Wei XB, He SM, Liang HJ, Yang HX, et al. Selected polymorphisms of GSTP1 and TERT were associated with glioma risk in Han Chinese. Cancer Epidemiol. 2012;36:525–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Custodio AC, Almeida LO, Pinto GR, Santos MJ, Almeida JR, Clara CA, et al. GSTP1 Ile105Val polymorphism in astrocytomas and glioblastomas. Genet Mol Res. 2010;9:2328–34.CrossRefPubMedGoogle Scholar
  26. 26.
    Yang ZH, Dai Q, Kong XL, Yang WL, Zhang L. Association of ERCC1 polymorphisms and susceptibility to nasopharyngeal carcinoma. Mol Carcinog. 2009;48:196–201.CrossRefPubMedGoogle Scholar
  27. 27.
    McKean-Cowdin R, Barnholtz-Sloan J, Inskip PD, Ruder AM, Butler M, Rajaraman P, et al. Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiol Biomarkers Prev. 2009;18:1118–26.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, Decker PA, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet. 2009;41:905–8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yu-Shu Dong
    • 1
    • 2
  • Wu-Gang Hou
    • 3
  • Xiao-Lan Li
    • 4
  • Tian-Bo Jin
    • 4
  • Yue Li
    • 5
  • Da-Yun Feng
    • 1
  • De-Bao Liu
    • 5
  • Guo-Dong Gao
    • 1
  • Zhong-Min Yin
    • 2
  • Huai-Zhou Qin
    • 1
  1. 1.Department of Neurosurgery, Tangdu HospitalThe Fourth Military Medical UniversityXi’anChina
  2. 2.Department of Neurosurgery463rd Hospital of PLAShenyangChina
  3. 3.Department of Anesthesiology, Xijing HospitalThe Fourth Military Medical UniversityXi’anChina
  4. 4.National Engineering Research Center for Miniaturized Detection Systems, School of Life SciencesNorthwest UniversityXi’anChina
  5. 5.Department of Air Logistics463rd Hospital of PLAShenyangChina

Personalised recommendations